Reed Jobs would rather talk cancer cures than his last name
Reed Jobs would rather discuss curing cancer than his famous last name. In a new TechCrunch interview, the founder of Yosemite—the oncology venture firm he launched in 2023—said he wants the organization judged on science, not lineage. Nearly three years after debuting at TechCrunch Disrupt, Jobs argues AI is accelerating drug discovery and clinical trial design faster than he expected, making this moment both urgent and empowering.
When a producer asked whether a MacBook was used during the video call, Jobs shot back: "Are you serious?" The exchange captures his impatience with celebrity framing. He cares far more about Yosemite's momentum in oncology—a sector that represents roughly 40% of biotech—than about being defined by his surname.
Key Takeaways
- Reed Jobs prefers discussing Yosemite's cancer work over his family legacy in interviews.
- Yosemite combines philanthropy and venture capital to build oncology startups from university research.
- Two of Yosemite's first 20 portfolio companies originated from no-strings philanthropic grants.
- Jobs says AI is speeding drug discovery and clinical trial design beyond his initial expectations.
- Once-elusive cancer targets like p53, KRAS, and beta-catenin are now within reach, he says.
Why does Reed Jobs avoid talking about his last name?
Jobs told TechCrunch that lineage is a distraction from the work that matters. Yosemite is entering a period of "extreme activity," with new partners and traction that he did not anticipate moving this quickly.
He frames the stakes personally and professionally: cures are not waiting inside big pharma archives. Teams must build them from fresh academic knowledge—and he would rather the conversation stay there.
What is Yosemite and how does it fund cancer research?
Yosemite is an oncology-only venture organization Jobs spun out in 2023, when biotech was still recovering from post-pandemic turbulence. Unlike firms that mostly back existing startups, Yosemite often creates its own companies from early university lab ideas.
To de-risk those fragile concepts, Yosemite deploys philanthropic capital with no strings attached alongside traditional outside investment. Jobs said two companies in Yosemite's first fund of 20 came directly from grants—a model he highlights as central to the firm's identity.
How is AI accelerating Reed Jobs' oncology bets?
Jobs credited artificial intelligence with expanding Yosemite's opportunity set. AI is influencing both drug discovery pipelines and how clinical trials are designed, compressing timelines that once slowed oncology progress.
He also pointed to broader scientific shifts. GLP-1 drugs and renewed attention to obesity as a "pan-disease" risk factor—alongside smoking—are pushing investors to revisit cold targets. Genes in the "pantheon of oncogenes" such as p53, KRAS, and beta-catenin, which evaded effective drugs for decades, now look reachable.
For readers tracking how technology reshapes medicine, this sits alongside broader coverage in our Future Tech & AI Wonders section.
What does Reed Jobs see ahead for cancer drug discovery?
Jobs said he did not expect Yosemite to be moving this fast. "This time is more important than I realized," he told TechCrunch, calling the current window both scarier and more empowering.
His message is consistent: judge Yosemite on whether it can turn gentle academic ideas into companies that attack cancer, not on the surname on his ID. In a field where AI and refreshed biology are reopening hard targets, that focus may be the story that outlasts the headline.